1 billion large varieties + 2.5 billion fundraising! Gan Li Pharmaceuticals breaks through the IPO to fight for the domestic insulin king

The wonderful content comes a few days ago, Ganli Pharmaceutical Co., Ltd (hereinafter referred to as: Ganli pharmaceutical) disclosed the prospectus (application draft) on the website of the CSRC, and it hit the capital market again four years later If listed successfully, Ganli pharmaceutical will be the second A-share listed company focusing on insulin drug production after Tonghua Dongbao According to the data, the domestic sales of changxiulin preparation of Ganli pharmaceutical in 2016 reached 1.632 billion yuan In addition, it is planned to use 2.5 billion yuan to raise funds for eight major projects, including the U.S registration and listing of recombinant insulin glargine products, the industrialization of insulin, and the U.S registration and listing of recombinant insulin products Top 20 manufacturers of terminal insulin and similar drugs in public medical institutions in China in 2016 According to the data of minenet, in 2016, the top 20 manufacturers of insulin and similar drugs in China's public medical institutions terminals (including China's urban public hospitals, county-level public hospitals, urban community centers and township health centers) accounted for the main market share of Novo Nordisk, Sanofi and Lilly, while Tonghua Dongbao ranked the first among domestic pharmaceutical enterprises, and Ganli pharmaceutical industry ranked the first Follow closely   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> a billion varieties of sweet plum pharmaceutical industry in recent years (unit: 10000 yuan) sweet plum pharmaceutical industry is mainly engaged in research, development, production and sales of raw materials and injections of recombinant insulin analogues The main products include recombined insulin glargine injection (trade name: changxiulin), recombined insulin laiproline injection (trade name: suxiulin), and recombined insulin laiproline mixture injection (25R) Its operating revenue reached 1.22 billion yuan in 2015, exceeded 1.5 billion yuan in 2016, and reached nearly 1 billion yuan in the first half of 2017; its net profit increased from 447 million yuan in 2015 to 770 million yuan in 2016, a year-on-year increase of 72% Equity relationship of Ganli pharmaceutical According to the data, in 2011, Tonghua Dongbao transferred all 29.43% of its shares in Ganli pharmaceutical According to the agreement between the two parties, Ganli pharmaceutical will obtain the patent and proprietary technology of the second generation insulin, and be allowed to be listed and sold in 42 months; Tonghua Dongbao will obtain the patent production technology of the third generation insulin, and be allowed to be listed and sold in 42 months Ganzhongru, the controlling shareholder and actual controller of Ganli pharmaceutical, controls 44.46% of the company's equity through direct and indirect shareholding Prior to this issuance, it directly held 126.5251 million shares of Ganli pharmaceutical, accounting for 35.06% of the total share capital; in addition, it held 64.53% of the equity of xutehongda, the shareholder of the company, and xutehongda held 33.9246 million shares of Ganli pharmaceutical, accounting for 9.40% of the total share capital It is understood that Gan Zhongru led his research and development team to develop the first recombinant human insulin in China in 1998 Since then, he has completed the development of the first quick acting recombinant insulin analogue suxiulin and long-acting recombinant insulin analogue changxiulin in China List of main products of Ganli pharmaceutical Changxiulin is a long-acting recombinant insulin analogue, which can last for 24 hours after the injection takes effect; shuxiulin can take effect quickly and eliminate it quickly, which is more in line with the action mode of human physiological meal insulin; the chemical structure of the active ingredient in the mixed injection of protamine zinc recombinant insulin (25R) is the same as that of shuxiulin, which is lysine insulin, which takes effect quickly after subcutaneous injection It is a kind of medium effect insulin Sales of main products of Ganli pharmaceutical industry: the operating revenue of Ganli pharmaceutical industry mainly comes from the sales revenue of insulin preparation and insulin dry powder In the past two years, the sales revenue of insulin preparation accounts for more than 95% of the main business revenue The terminal market of its insulin products is mainly hospital market, and the sales revenue of 2016 senior Xiulin preparation in China reached 1.632 billion yuan   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> the research projects in progress are concentrated in the field of diabetes mellitus In order to maintain its competitive advantage in the field of insulin, the R & D investment in the industry has increased year by year In 2015, the R & D expenditure accounted for 4.11% of the revenue, 5.41% in 2016 and 9.18% in the first half of 2017 Its research projects focus on the field of diabetes, and build a research and development system covering pre clinical research, clinical research, registration and approval, pilot scale-up, industrial research and other stages to further enrich the company's insulin product structure Ganli pharmaceutical said that by setting up R & D institutions in developed countries in Europe and the United States and other ways to improve and enhance its R & D capacity, through the establishment of a pilot innovation platform and the allocation of fully used pilot scale-up equipment, it laid a solid foundation for promoting the industrialization of new drugs for diabetes and diabetic complications, so as to establish a leading domestic technical advantage in the field of diabetes treatment and prevention   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> 2.5 billion raised funds are used for eight projects overview of investment projects raised by Ganli pharmaceutical industry (unit: 10000 yuan) Ganli pharmaceutical industry plans to use 2.519 billion yuan raised funds for eight projects, including the U.S registration and listing of recombinant insulin products, insulin industrialization, and the U.S registration and listing of recombinant insulin products, with a total investment of 2.582 billion yuan Among them, the investment in two major projects of insulin industrialization and recombination of insulin products registered and listed in the United States exceeded 1 billion yuan, accounting for nearly 40% of the total investment Ganli pharmaceutical said that the sales of its main products, recombinant insulin analogues, are growing rapidly, while new products under development will be launched into the market in succession, and the production capacity will not be able to meet the continuous growth of future sales Therefore, the company invests 593 million yuan in the construction of insulin industrialization project At present, the project has started construction, and the company plans to use the raised funds to replace the initial investment of the project In addition, to apply for registration and marketing in the United States, lispro insulin injection needs to complete pre clinical research, clinical research, GMP certification inspection of commercial production scale, and obtain FDA approval The company plans to invest about 415 million yuan in restructuring lispro insulin products registered in the United States Ganli pharmaceutical industry has occupied a certain market share in the insulin market and maintained rapid growth It is reported that Ganli pharmaceutical plans to develop innovative drugs with completely independent intellectual property rights in the next 5-10 years and enter the market of developed countries In addition, the development of oral hypoglycemic drugs and medical devices will be strengthened It is expected that the production capacity of oral hypoglycemic drugs and diabetes related medical devices will be formed in the future, and the products of the three major product lines in the field of diabetes diagnosis and treatment will be put on the market in an all-round way to further improve their profitability and market competitiveness Data source: advanced database and prospectus declaration draft of minenet